Zeria Pharmaceutical (4559) · InitiativeChange of company name after acquisition
Acquisition of 日水製薬医薬品販売 to Ensure Stable Procurement of Hepalyse Ingredients and Expand the Business
First written in FY2020-Q3. 1 of 3 entries say "Achieved", first in FY2020. Latest entry: FY2021-Q1.
3entries
1years
0from disclosures
How it moved
Same theme, other companies
Securing a stable supply of Hepalyse ingredients and expanding the consumer healthcare business through the conversion of 日水製薬医薬品販売 into a subsidiaryA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2021-Q1Change of company name after acquisitionAnnual report
「The company changed its name to 健創製薬株式会社 on 29 June 2020.」
Following the acquisition of all shares and its conversion into a subsidiary on 1 April 2020, Nissui Pharmaceutical Sales changed its name to 健創製薬株式会社 on 29 June 2020. - FY2020AchievedAnnual report
「Under the agreement, the Company acquired all shares of Nissui Pharmaceutical Sales on 1 April 2020 and made it a subsidiary.」
The Company acquired all shares of Nissui Pharmaceutical Sales on 1 April 2020 and made it a subsidiary. The acquisition, intended to secure a stable supply of Hepalyse's key raw material and expand the consumer healthcare business, was completed. - FY2020-Q3First statedAnnual report
「The Company has decided to acquire all shares of Nissui Pharmaceutical Sales, a subsidiary of Nissui Pharmaceutical, with the aim of securing a stable supply of liver hydrolysate, the key raw material essential to the future growth of the Hepalyse product family, and expanding its consumer healthcare business by bringing Nissui Pharmaceutical Sales' pharmaceutical business under its control.」
The Company entered into a share transfer agreement dated 17 January 2020 to acquire all shares of Nissui Pharmaceutical Sales, with the acquisition scheduled for 1 April 2020. The acquisition price is ¥3.3 billion, the ownership ratio after the acquisition will be 100%, and the acquisition is intended to secure a stable supply of Hepalyse's key raw material and expand the consumer healthcare business.